argenx SE (ARGX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

argenx SE (ARGX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

665.84

-4.56 (-0.68%)

At close: Jan 14, 2025, 3:59 PM

665.60

-0.04%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	658.8
Market Cap	40.20B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.8
PE Ratio (ttm)	-832.3
Forward PE	n/a
Analyst	Buy

Ask	660
Volume	348,245
Avg. Volume (20D)	270,642
Open	667.71
Previous Close	670.40
Day's Range	664.12 - 678.21
52-Week Range	349.86 - 678.21
Beta	undefined

About ARGX

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 18, 2017

Employees 1,148

Stock Exchange NASDAQ

Ticker Symbol ARGX

Website https://www.argenx.com

Analyst Forecast

According to 20 analyst ratings, the average rating for ARGX stock is "Buy." The 12-month stock price forecast is $672.5, which is an increase of 1.00% from the latest price.

Buy 95.00%

Hold 5.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

argenx SE is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of $613.67M, reflecting a 46.87% YoY growth and earnings per share of 1.06, making a -163.10% decrease YoY.

Why Price Moved

1 month ago · Source

+3.01%

Argenx shares are trading higher after the company... Unlock content with Pro Subscription

2 months ago · Source

+2.34%

Argenx shares are trading higher after Scotiabank upgraded the stock from Sector Perform to Sector Outperform and raised its price target from $439 to $715.

News

23 hours ago · zacks.com

Are Medical Stocks Lagging Argenx (ARGX) This Year?

Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.

2 months ago · https://thefly.com

Argenx upgraded to Outperform from Peer Perform at Wolfe Research

Wolfe Research upgraded Argenx to Outperform from Peer Perform.

2 months ago · businesswire.com

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMP...

2 months ago · zacks.com

Why Argenx (ARGX) Might be Well Poised for a Surge

Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

2 months ago · zacks.com

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.

2 months ago · seekingalpha.com

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

argenx reported strong Q3 results with the sales outperformance being primarily driven by the gMG uptake of Vyvgart. Initial contribution from the CIDP launch also exceeded expectations. The growth ou...

2 months ago · seekingalpha.com

argenx SE (ARGX) Q3 2024 Earnings Call Transcript

argenx SE (NASDAQ:ARGX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Beth DelGiacco – Vice President, Corporate Communications and Investor Relations Tim Van Hauw...